NCT02669251View on ClinicalTrials.gov

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 28, 2016

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions

Chronic Graft vs Host DiseaseChronic Graft-Versus-Host DiseaseBronchiolitis Obliterans Syndrome

Interventions

DRUG

MPH966

"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID~Phase 2 Cycle=28 days: MTD PO BID"

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT02669251 - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter